Bulgaria has significantly reduced hospitalisations by providing fully reimbursed medicines for cardiovascular diseases, according to new data from the National Health Insurance Fund.
In April 2024, Bulgaria took significant steps to address the high burden of cardiovascular diseases (CVD) by announcing a comprehensive reform in its healthcare system. The state pledged full coverage of costs for 56 essential drugs specifically aimed at treating CVD, while also subsidizing over 300 additional medications by more than 90%. This initiative resulted in a drastic reduction of patient co-payments to just 50 euro cents for certain medicines, making vital treatments more accessible.
The Bulgarian National Health Insurance Fund (NHIF) reported a marked improvement in patient outcomes, with an additional 30,000 individuals effectively managing their cardiovascular conditions following the 100% reimbursement policy. This improved adherence to therapy correlated with fewer hospitalizations due to complications. The investment of 25 million euros over nine months not only aimed to enhance health outcomes but also projected significant economic benefits—estimated at around 1.3 billion euros—based on the productivity gains from healthier patients.
Despite these advancements, Bulgaria remains an outlier in the EU regarding cardiovascular mortality rates. While circulation disease deaths decreased across most EU countries from 2011 to 2021, Bulgaria’s figures rose, highlighting a concerning trend in public health. Factors contributing to this high mortality include prevalent high-risk behaviors, such as smoking and alcohol consumption, along with the nation’s struggle with antibiotic resistance. The healthcare system in Bulgaria faces challenges, particularly regarding out-of-pocket expenses during critical times for patients. Households in Bulgaria experience catastrophic health costs—at 19.2%, the highest in the EU—often when individuals are most vulnerable, such as during chronic illness or major medical procedures.
In early 2024, the Bulgarian parliament adopted a new health strategy aimed at reducing premature deaths by 55% by 2030, with a major focus on cardiovascular health and the treatment of oncological diseases. This strategy includes measures to ensure patients have access to essential therapies and aims to minimize co-payments for state-funded treatments.
Additionally, the implementation of a pro-generic drug policy is part of this strategy to stimulate competition and lower public pharmaceutical costs, indicating a commitment to improving healthcare access and outcomes for Bulgarian citizens.
